Skip to main content
Equibles
RNXT logo

RNXT · RenovoRx, Inc. · Webcasts, Transcripts & Audio

Track RNXT — free

Use RNXT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RNXT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.58 +0.00 (+0.00%)
Rebalance outlook locked
Market Cap
$74.91M
Shares
45.13M
Volume · Oct 2 269.37K Avg daily vol (3M) 745.21K

RenovoRx, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for RenovoRx, Inc. (RNXT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $197,000 −$2.42M '25 Q1 25-05-15 · $422,000 −$2.90M '25 Q2 25-08-14 · $266,000 −$2.91M '25 Q3 25-11-13 · $238,000 −$2.94M '25 Q4 26-03-30 ▲185.8% $563,000 −$3.52M '26 Q1 26-05-14 LATEST ▲115.4% $909,000 −$2.91M '26 Q2 26-08-12
Conference
Investor event
2026-09-14
RenovoRx, Inc. (RNXT) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-12
RenovoRx, Inc. (RNXT) Q2 2026 Earnings Call Transcript
Confident tone TigerPAC Phase III trial progress Expansion beyond pancreatic cancer Record quarterly revenue growth
Revenue
$909,000
▲ 115.4% YoY
Diluted EPS
$-0.06
Gross margin
84.3%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-23
RenovoRx, Inc. (RNXT) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-14
RenovoRx, Inc. (RNXT) Q1 2026 Earnings Call Transcript
Confident tone Revenue growth and commercial momentum TIGeR-PaC Phase III trial progress RenovoCath / TAMP therapy platform
Revenue
$563,000
▲ 185.8% YoY
Diluted EPS
$-0.09
Gross margin
85.1%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-30
RenovoRx, Inc. (RNXT) Q4 2025 Earnings Call Transcript
Confident tone Revenue ramp and trajectory Commercial site expansion and pipeline TAMP / RenovoCath platform adoption
Revenue
$238,000*
Gross margin
88.2%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
RenovoRx, Inc. (RNXT) Q3 2025 Earnings Call Transcript
Confident tone TIGER PACT Phase III trial Commercial adoption of RenovoCath TAMP therapy platform
Revenue
$266,000
Diluted EPS
$-0.08
Gross margin
80.1%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
RenovoRx, Inc. (RNXT) Q2 2025 Earnings Call Transcript
Confident tone RenovoCath commercial launch and revenue Phase III TIGR PACT trial progress DMC interim analysis recommendation
Revenue
$422,000
Diluted EPS
$-0.08
Gross margin
64.0%
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
RenovoRx, Inc. (RNXT) Q1 2025 Earnings Call Transcript
Confident tone RenovoCath commercial launch and revenue Phase 3 TIGeR-PaC clinical trial progress TAMP therapy platform and IP
Revenue
$197,000
Diluted EPS
$-0.08
Gross margin
52.3%
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-30
RenovoRx, Inc. (RNXT) Q4 2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–9 of 9 webcasts
Key facts CIK 1574094 CUSIP 75989R107 13F (30d) 1 filings 1 filers Visit website Investor relations